SS&C to attend Sandler O’Neill, William Blair Conferences

WINDSOR, Conn., June 3, 2019 /PRNewswire/ — SS&C Technologies Holdings, Inc. (Nasdaq: SSNC), a global provider of software and software-enabled services for the financial services and healthcare industries, today announced that Patrick Pedonti, Chief Financial Officer, will attend the Sandler O’Neill Global Exchange and Brokerage Conference on Wednesday, June 5th, 2019 at the Parker New York, in New York, NY.

SS&C will also attend the William Blair 39th Annual Growth Stock Conference. Rahul Kanwar, President and Chief Operating Officer will speak at the William Blair Conference on Thursday, June 6th, 2019 at the Loews Chicago Hotel, in Chicago, IL at 8:40 AM CT.

Webcast and presentation materials will be made available on SS&C Technologies’ investor relations website at http://investor.ssctech.com.

About SS&C Technologies
SS&C is a global provider of investment and financial software-enabled services and software for the global financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut and has offices around the world. Some 18,000 financial services and healthcare organizations, from the world’s largest institutions to local firms, manage and account for their investments using SS&C’s products and services.

Additional information about SS&C (Nasdaq:SSNC) is available at www.ssctech.com.  
Follow SS&C on Twitter, Linkedin and Facebook.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ssc-to-attend-sandler-oneill-william-blair-conferences-300860311.html

SOURCE SS&C

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

18 minutes ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

18 minutes ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

18 minutes ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

18 minutes ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

18 minutes ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

18 minutes ago